nimodipine has been researched along with Cerebrovascular Moyamoya Disease in 2 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, YM | 1 |
| Xie, CH | 1 |
| Gong, FQ | 1 |
| Spittler, JF | 1 |
| Smektala, K | 1 |
2 other studies available for nimodipine and Cerebrovascular Moyamoya Disease
| Article | Year |
|---|---|
Moyamoya disease associated with aortic coarctation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Coarctation; Aspirin; Calcium Channel Blocker | 2014 |
Pharmacotherapy in moyamoya disease.
Topics: Adrenal Cortex Hormones; Adult; Arterial Occlusive Diseases; Cerebral Angiography; Drug Therapy, Com | 1990 |